February 27, 2021
ARLINGTON, Va. — HDA President and CEO Chester “Chip” Davis, Jr., released a statement regarding the U.S. Food and Drug Administration’s (FDA) granting of an Emergency Use Authorization (EUA) for the Johnson & Johnson (Janssen Biotech) COVID-19 vaccine candidate.
“FDA’s authorization of a third COVID-19 vaccine candidate — a one-dose formulation — delivers additional hope that we will be able to provide more Americans greater access to vaccines while slowing the rate of infection. HDA appreciates the hard work of our manufacturer trading partners and the FDA in providing another option that strengthens the country’s fight against this virus.
“HDA members already are integrally engaged in distributing COVID-19 related medical supplies, PPE, therapeutics and vaccines across the U.S. As an industry, we stand ready to do more. Leveraging strong relationships with 1,400 manufacturers and more than 180,000 providers, distributors have the capacity, infrastructure and customer networks to move billions of products where they are most needed, with the ability to mobilize quickly. As the Biden administration ramps up this historic vaccination campaign, our members will continue to engage with federal and state governments to help deliver vaccines safely and efficiently to communities far and wide.”
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.